Combination therapy in fibromyalgia

A H Clayton1, S G West

  • 1Department of Psychiatric Medicine, University of Virginia, Charlottesville, VA 22908-0623, USA. ahc8v@virginia.edu

Insights

Fibromyalgia, a complex condition affecting millions, likely stems from multiple factors. Effective treatment requires a personalized, combined approach for maximum patient benefit.

Area of Science:

  • Rheumatology
  • Neuroscience
  • Pain Management

Background:

  • Fibromyalgia is a chronic condition affecting millions of Americans.
  • Its exact cause (etiology) is still unknown.
  • The condition is characterized by widespread pain and other symptoms.

Purpose of the Study:

  • To review the multifactorial nature of fibromyalgia.
  • To emphasize the need for tailored treatment strategies.
  • To highlight the benefits of combination therapy.

Main Methods:

  • Literature review of current fibromyalgia research.
  • Analysis of etiological factors.
  • Evaluation of treatment outcomes.

Main Results:

  • Evidence suggests fibromyalgia has multiple contributing factors.
  • No single cause has been identified.
  • Combined treatment approaches show greater efficacy.

Conclusions:

  • Fibromyalgia's multifactorial origin necessitates individualized treatment plans.
  • Combining different therapeutic modalities is crucial for optimal symptom management.
  • Further research into fibromyalgia etiology and treatment is warranted.

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...